Zehna Therapeutics Inc

Zehna Therapeutics Inc. is a small, privately held biotech company headquartered in the United States. With a team of three employees, the company focuses on the research and development of novel therapeutic solutions. Zehna Therapeutics specializes in developing non-bacteriocidal inhibitors targeting specific gut microbial pathways implicated in chronic metabolic diseases. Their primary focus is on inhibiting the gut microbial enzyme CutC, which prevents the conversion of dietary choline to trimethylamine and subsequently to trimethylamine N-oxide (TMAO) in the host. High levels of TMAO have been scientifically linked to the accelerated development of cardiovascular and chronic kidney disease, as evidenced by extensive clinical cohort studies. This understanding drives Zehna Therapeutics' dedication to developing therapies that address the underlying microbial mechanisms contributing to these serious health conditions. For more information about Zehna Therapeutics Inc. and their innovative approach to treating chronic metabolic diseases, please visit their website at zehnatx.com.